Long noncoding RNA BC200 regulates cell growth and invasion in colon cancer

Wu, Ke; Xu, Kaiwu; Liu, Kuanzhi; Huang, Jiehong; Chen, Jianhui; Zhang, Jian; Zhang, Ning

doi:10.1016/j.biocel.2018.04.001

Cited by 54 publications

(48 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that study, the authors found BC200 expression to be substantially increased in certain tumours, like breast, cervix, oesophagus, lung, ovary, parotid and tongue, while it is undetectable in corresponding normal tissues and in other cancers, such as bladder, colon and liver [ 26 ]. More recent investigations propose that BC200 has roles in cell migration, proliferation and survival [ [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] ] – all suggesting that BC200 contributes to cancer development and progression.…”

Section: Introductionmentioning

confidence: 99%

BC200 (BCYRN1) – The shortest, long, non-coding RNA associated with cancer

Samson

Cronin

Dean

2018

Non-coding RNA Research

View full text Add to dashboard Cite

With the discovery that the level of RNA synthesis in human cells far exceeds what is required to express protein-coding genes, there has been a concerted scientific effort to identify, catalogue and uncover the biological functions of the non-coding transcriptome. Long, non-coding RNAs (lncRNAs) are a diverse group of RNAs with equally wide-ranging biological roles in the cell. An increasing number of studies have reported alterations in the expression of lncRNAs in various cancers, although unravelling how they contribute specifically to the disease is a bigger challenge. Originally described as a brain-specific, non-coding RNA, BC200 (BCYRN1) is a 200-nucleotide, predominantly cytoplasmic lncRNA that has been linked to neurodegenerative disease and several types of cancer. Here we summarise what is known about BC200, primarily from studies in neuronal systems, before turning to a review of recent work that aims to understand how this lncRNA contributes to cancer initiation, progression and metastasis, along with its possible clinical utility as a biomarker or therapeutic target.

show abstract

Section: Introductionmentioning

confidence: 99%

BC200 (BCYRN1) – The shortest, long, non-coding RNA associated with cancer

Samson

Cronin

Dean

2018

Non-coding RNA Research

View full text Add to dashboard Cite

show abstract

“…These data are consistent with previous reports indicating that BCYRN1 also acts as an oncogene in other cancers, such as cervical and colon cancer. 21,22 The ceRNA hypothesis has provided a network regulatory model for ceRNA-miRNA-mRNA interactions, and emerging data have revealed that lncRNAs can act as ceRNAs to regulate biological processes in many cancers. 14,15,25,26 Interestingly, Peng et al reported that decreasing BCYRN1 expression attenuates the viability and motility of cervical cancer cells through targeting of miR-138.…”

Section: Discussionmentioning

confidence: 99%

“…20 Recent studies have found that BCYRN1 is more highly expressed in breast, ovarian, colon, cervical and other cancer tissues than in corresponding normal tissues, and BCYRN1 is related to the tumorigenesis and prognosis of these cancers. 21,22 Our previous studies have shown that BCYRN1 is significantly downregulated during genotoxic stressinduced necrosis in U87 and U251 cells, indicating that BCYRN1 may have oncogenic potential in glioma cells. 23 In the present study, we report that BCYRN1 can promote glioma cell proliferation, invasion and migration in vitro.…”

Section: Introductionmentioning

confidence: 98%

<p>The lncRNA BCYRN1 Functions as an Oncogene in Human Glioma by Downregulating miR-125a-5p in vitro</p>

Xiang

Jia

et al. 2020

CMAR

View full text Add to dashboard Cite

Introduction: Numerous studies have demonstrated that long noncoding RNAs (lncRNAs) are deregulated in many cancers and exert their functions through multiple cancer-related biological processes. Glioma is the most common primary malignant central nervous system tumor and has a high fatality rate in adults. In current study, we aimed to determine the role and functional mechanism of the lncRNA BCYRN1 in glioma. Methods: Gain-of-function and loss-of function approaches were used to investigate the function of BCYRN1. The effects of BCYRN1 on glioma cell proliferation, migration and invasion were evaluated using MTS, Transwell and wound-healing assays. The correlation between the expression of BCYRN1 and miR-125a-5p was verified by quantitative real-time PCR. Results: The upregulation of BCYRN1 promoted the proliferation, migration and invasion of glioma cells. Meanwhile, the knockdown of BCYRN1 had the opposite effects. BCYRN1 was negatively correlated with miR-125a-5p. Additionally, TAZ, the endogenous target of miR-125a-5p, could be regulated by BCYRN1 in RNA and protein levels. A miR-125a-5p inhibitor restored BCYRN1 siRNA function in glioma. Conclusion: The present study indicates that BCYRN1 promotes glioma cell proliferation, invasion and migration in vitro. Mechanistically, upregulated expression of BCYRN1 in glioma acts as a sponge to sequester the endogenous tumor suppressor miR-125a-5p and to further increase the expression TAZ. Our findings suggest that BCYRN1 is a novel oncogene and a new therapeutic target for glioma.

show abstract

“…A long non-coding RNAs (lncRNAs), the maternally expressed gene 3 ( MEG3 ) is involved in diverse cellular processes including cell proliferation, migration and invasion and is present in multiple cancer cell types including prostate, breast, colorectal, gastrointestinal and pancreatic [ 8 ]. The role of lncRNAs in tumor progression is another hot topic nowadays, several reports from the literature demonstrating that these genes have either a protective effect, such as the case of MEG3 whose low levels were associated with increased incidence of liver metastasis [ 9 ] or a stimulative effect, such as the case of BC200, another lncRNAs, which is up-regulated in colon cancer tissue, its knockdown inhibiting proliferation and invasion of certain cancer cells lines [ 10 ]. The authors of the present paper have found that MEG3 over-expression suppressed colorectal cancer cell (CRC) proliferation and metastasis in-vivo and in-vitro, that it reduced transcription of clusterin, a protumoral protein, in CRC cells and that vitamin D achieved its anti-tumoral role by activating MEG3 expression in CRC cells via its nuclear receptor (VDR).…”

mentioning

confidence: 99%

Vitamin D as a Potential Therapeutic Target and Prognostic Marker for Colorectal Cancer

Bințințan

2018

EBioMedicine

View full text Add to dashboard Cite

Long noncoding RNA BC200 regulates cell growth and invasion in colon cancer

Cited by 54 publications

References 20 publications

BC200 (BCYRN1) – The shortest, long, non-coding RNA associated with cancer

BC200 (BCYRN1) – The shortest, long, non-coding RNA associated with cancer

<p>The lncRNA BCYRN1 Functions as an Oncogene in Human Glioma by Downregulating miR-125a-5p in vitro</p>

Vitamin D as a Potential Therapeutic Target and Prognostic Marker for Colorectal Cancer

Contact Info

Product

Resources

About